Press "Enter" to skip to content

U.S. Medicare plans to track CAR-T cancer therapy outcomes

The U.S. Centers for Medicare & Medicaid Services (CMS) on Friday proposed coverage of expensive CAR-T cell therapies at cancer centers that meet criteria including a registry or clinical study to monitor how well patients fare for at least two years after treatment.

Also Read:   ‘No one can speed up vaccine trials, and their evaluation’